Promising drug cocktail aims to boost esophageal cancer surgery success
NCT ID NCT07505186
First seen Apr 11, 2026 · Last updated May 14, 2026 · Updated 5 times
Summary
This study tests whether giving a combination of three drugs (camrelizumab, chemotherapy, and ivarmacitinib) before surgery can help people with a type of esophageal cancer. The goal is to shrink or eliminate tumors before removal, potentially improving outcomes. About 45 adults with stage II to IVA esophageal squamous cell carcinoma will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, China, 310009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.